



Korean Guidelines for the Management of Dyslipidemia 5th

Committee of Clinical
Practice Guideline of
the Korean Society of Lipid
and Atherosclerosis



KSoLA
The Korean Society of Lipid and Atherosclerosis



Contents

Criteria for the classification of dyslipidemia	3
Major risk factors of atherosclerotic cardiovascular disease other than LDL-C	4
Recommendations for treatment goals of LDL-C and non-HDL-C	5
Treatment strategies according to risk categories and LDL-C	6
Dietary recommendation	7
Exercise prescription for patients with dyslipidemia	8
Evidence-guided approach algorithm of dyslipidemia treatment	9
Secondary causes of hypercholesterolemia or hypertriglyceridemia	10
Lipid-lowering efficacy and pharmacologic characteristics of statins	11
Summary of statin use	12
LDL-C lowering effect of statins in Koreans	13
Dutch lipid clinic network criteria for familial hypercholesterolemia	14
Simon Broome diagnostic criteria for familial hypercholesterolemia	15

Criteria for the classification of dyslipidemia



Unit: mg/dL

Total Cholesterol	LDL Cholesterol	Triglyceride	HDL Cholesterol
High ≥ 240	Very High ≥ 190	Very High ≥ 500	Low < 40
Border-line 200~239	High 160~189	High 200~499	High ≥ 60
Optimal < 200	Border-line 130~159	Border-line 150~199	
	Normal 100~129	Optimal < 150	
	Optimal < 100		

Major risk factors of atherosclerotic cardiovascular disease other than LDL-C¹⁾



Age

(men ≥ 45 ; women ≥ 55 years)



Family history of premature coronary artery disease

If any of the parents or siblings (men < 55 ; women < 65 years) has coronary artery disease



Hypertension

(blood pressure $\geq 140/90$ mmHg or on antihypertensive medication)



Smoking



Low HDL cholesterol level

(< 40 mg/dL)

¹⁾ High HDL cholesterol level (≥ 60 mg/dL) is considered as a protective factor, and one factor is excluded from the total number of risk factors.

LDL-C, low-density lipoprotein cholesterol ; HDL-C, high-density lipoprotein cholesterol.

Recommendations for treatment goals of LDL-C and non-HDL-C



Risk category	LDL-C (mg/dL)	non-HDL-C (mg/dL)
Coronary artery disease ^{1)*}	< 55	< 85
Atherosclerotic stroke and transient ischemic attack* Carotid artery disease* Peripheral artery disease* Abdominal aortic aneurysm* Diabetes mellitus (duration ≥ 10 years or major risk factor [†] or target organ damage) ²⁾	< 70	< 100
Diabetes mellitus (duration < 10 years and no major risk factors [†])	< 100	< 130
Moderate risk (major risk factors [†] ≥ 2)	< 130	< 160
Low risk (major risk factors [†] ≤ 1)	< 160	< 190

*It is also recommended to reduce LDL-C by ≥ 50% from the baseline level.

[†]Age (men ≥ 45 years, women ≥ 55 years), family history of premature ASCVD, hypertension, smoking, and low HDL-C level (< 40 mg/dL).

¹⁾ In patient with acute myocardial infarction, statin is recommended irrespective of LDL-C level.

²⁾ In diabetes mellitus with target organ damage (albuminuria, CKD [eGFR <60 mL/min/1.73m²], retinopathy, neuropathy, left ventricular hypertrophy) or major risk factors[†] ≥ 3: target LDL-C < 55 mg/dL (optional)

LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.

Treatment strategies according to risk categories and LDL-C



Risk category	LDL-C (mg/dL)					
	<55	55-69	70-99	100-129	130-159	≥ 160
Coronary artery disease^{1)*}	Lifestyle modification and consider drug	Lifestyle modification and concomitant drug intervention	Lifestyle modification and concomitant drug intervention	Lifestyle modification and concomitant drug intervention	Lifestyle modification and concomitant drug intervention	Lifestyle modification and concomitant drug intervention
Atherosclerotic stroke and transient ischemic attack* Carotid artery disease* Peripheral artery disease* Abdominal aortic aneurysm* Diabetes mellitus (duration ≥ 10 years or major risk factor[†] or target organ damage)²⁾	Lifestyle modification	Lifestyle modification and consider drug	Lifestyle modification and concomitant drug intervention	Lifestyle modification and concomitant drug intervention	Lifestyle modification and concomitant drug intervention	Lifestyle modification and concomitant drug intervention
Diabetes mellitus (duration < 10 years and no major risk factors[†])	Lifestyle modification	Lifestyle modification	Lifestyle modification and consider drug	Lifestyle modification and concomitant drug intervention	Lifestyle modification and concomitant drug intervention	Lifestyle modification and concomitant drug intervention
Moderate risk³⁾ (major risk factors[†] ≥ 2)	Lifestyle modification	Lifestyle modification	Lifestyle modification	Lifestyle modification and consider drug	Lifestyle modification and concomitant drug intervention	Lifestyle modification and concomitant drug intervention
Low risk³⁾ (major risk factors[†] ≤ 1)	Lifestyle modification	Lifestyle modification	Lifestyle modification	Lifestyle modification	Lifestyle modification and consider drug	Lifestyle modification and concomitant drug intervention

*It is also recommended to reduce LDL-C by ≥ 50% from the baseline level.

[†]Age (men ≥ 45 years, women ≥ 55 years), family history of premature ASCVD, hypertension, smoking, and low HDL-C level (< 40 mg/dL).


¹⁾ In patient with acute myocardial infarction, statin is recommended irrespective of LDL-C level.

²⁾ In diabetic patients with target organ damage (albuminuria, CKD [eGFR <60 mL/min/1.73m²], retinopathy, neuropathy, left ventricular hypertrophy) or major risk factors[†] ≥ 3 (optional).

³⁾ In groups with moderate and low risk, statin is considered when LDL-C is consistently high even after several weeks or months of lifestyle modification.


LDL-C, low-density lipoprotein cholesterol.

Dietary recommendation



 **Consume energy intake to maintain a healthy weight**


Consume a healthy dietary pattern with a focus on whole grains, legumes, vegetables, and fish



Consume whole grains as a staple food



Consume plenty of vegetables



Consume fish, lean meat, or legumes rather than red and processed meat



Consume fresh fruits

Exercise prescription for patients with dyslipidemia




	Aerobic exercise	Resistance exercise	Stretching exercise
Frequency	5 or more days a week to maximize calorie consumption	2-3 days a week	2-3 days or more a week
Intensity	Moderate to high intensity, 40-75% of heart rate reserve ^{1,2)}	Moderate (50-69% of 1 RM ³⁾) to high (70-85% of 1 RM ³⁾) intensity for muscle strengthening	To the extent that the stretched area feels tight or slightly uncomfortable
Duration	30-60 minutes a day (50-60 minutes a day for weight reduction)	For muscle strength improvement: 2-4 sets, 8-12 reps; for muscle endurance improvement: 2 sets or less, 12-20 reps	10-30 seconds, 2-4 reps
Example	Continuous and rhythmic activities that use the large muscles (walking, cycling, swimming, etc.)	Use of resistance exercise equipment, full-body resistance training, free weight exercise, etc.	Static and dynamic stretching exercise

1) Heart rate reserve = maximal heart rate – resting heart rate

2) How to calculate target heart rate = (220-age-resting heart rate) x exercise intensity (0.40~0.75) + resting heart rate

3) 1 RM (repetition maximum) = intensity/weight that can be performed once with the maximum effort of the individual

Evidence-guided approach algorithm of dyslipidemia treatment



LDL-C, low-density lipoprotein cholesterol;
PCSK9, Proprotein Convertase Subtilisin/Kexin type 9.

Secondary causes of hypercholesterolemia or hypertriglyceridemia



	Elevated LDL cholesterol	Elevated Triglyceride
Diet	<ul style="list-style-type: none"> • Intake of saturated fatty acid • Intake of trans fatty acid • High caloric intake 	<ul style="list-style-type: none"> • Alcohol drinking • High caloric intake • High carbohydrate intake
Drugs	<ul style="list-style-type: none"> • Diuretics • Glucocorticoid • Amiodarone • Cyclosporine 	<ul style="list-style-type: none"> • Oral estrogen • Bile acid sequestrant • Retinoic acid • Sirolimus • Tamoxifen • Thiazide diuretics • Glucocorticoid • Protease inhibitor • Anabolic steroid • Raloxifen • Beta-blocker
Disease	<ul style="list-style-type: none"> • Obstructive liver disease • Nephrotic syndrome • Anorexia nervosa 	<ul style="list-style-type: none"> • Chronic kidney disease • Nephrotic syndrome • Sepsis
Abnormal metabolism	<ul style="list-style-type: none"> • Obesity • Pregnancy • Hypothyroidism 	<ul style="list-style-type: none"> • Obesity • Pregnancy • Uncontrolled diabetes

Lipid-lowering efficacy and pharmacologic characteristics of statins



		Lovastatin	Pravastatin	Simvastatin	Atorvastatin	Fluvastatin	Rosuvastatin	Pitavastatin
Daily dose (mg)		20~40	10~40 ¹⁾	20~40	10~80	20~80	5~20 ²⁾	1~4
LDL-C reduction (%)	24~28	20	20			40		1
	30~36	40	40	20	10	80		2
	39~45	80		40	20		5~10	4
	46~52				40~80		20	
Metabolism		CYP3A4	Sulfonation	CYP3A4	CYP3A4	CYP2C9	CYP2C9	Glucuronidation (Partial CYP2C9)
Protein binding (%)		> 95	43~67	95~98	98	98	88	> 99
Half-life (h)		2~4	2~3	1~3	13~30	0.5~3	19	12
Hydrophilicity		-	+	-	-	-	+	-
Elimination		Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary
Renal elimination fraction (%)		10	20	13	< 2	< 6	28	15

1) 40~80 mg in Caucasian countries

2) 5~40 mg in Caucasian countries


Summary of statin use



Statin: HMG-CoA reductase inhibitor

Dosing	Lovastatin	20-80 mg once daily, take with dinner
	Pravastatin	10-40 mg once daily, more effective to take it in the evening
	Simvastatin	20-40 mg once daily, more effective to take it in the evening
	Fluvastatin	20-80 mg once daily, more effective to take it in the evening
	Atorvastatin	10-80 mg once daily, not significantly affected by the time taken
	Rosuvastatin	5-20 mg once daily, not significantly affected by the time taken
	Pitavastatin	1-4 mg once daily, not significantly affected by the time taken
Monitoring		Lipid profiles, liver function test and muscle enzyme (in case of unexplained myalgia or muscle weakness)
Adverse effect		Dyspepsia, epigastric soreness, abdominal pain, hepatotoxicity, myopathy and diabetes mellitus
Contraindication		It is absolutely contraindicated in pregnant or lactating women and active or chronic liver disease. It is relatively contraindicated when co-administered with other drugs such as cyclosporin, macrolide antibiotics, antifungals, and cytochrome P-450 inhibitors.

LDL-C lowering effect of statins in Koreans



Dutch lipid clinic network criteria for familial hypercholesterolemia



Criteria		Points
1) Family history	1st-degree relative with known premature (men < 55 years; women < 60 years) coronary or vascular disease, or 1st-degree relative with known LDL-C > 95th percentile	1
	1st-degree relative with tendinous xanthoma and/or arcus cornealis, or children < 18 years with LDL-C > 95th percentile	2
2) Clinical history	Patient with premature CAD	2
	Patient with premature cerebral or peripheral vascular disease	1
3) Physical examination	Tendon xanthoma	6
	Arcus cornealis at age <45 years	4
4) LDL-C (without treatment)	> 8.5 mmol/L (325 mg/dL)	8
	6.5-8.4 mmol/L (251-325 mg/dL)	5
	5.0-6.4 mmol/L (191-250 mg/dL)	3
	4.0-4.9 mmol/L (155-190 mg/dL)	1
5) DNA analysis	Functional mutation in the LDLR, APOB, or PCSK9 genes	8

Choose only one score per group, the highest applicable, diagnosis is based on the total number of points
 'definite' FH: ≥ 9 points / 'probable' FH: 6-8 points / 'possible' FH: 3-5 points

Simon Broome diagnostic criteria for familial hypercholesterolemia



Definite FH

Cholesterol criteria : < 16 years: total cholesterol > 260 mg/dL or LDL-C > 155 mg/dL
≥ 16 years: total cholesterol > 290 mg/dL or LDL-C > 190 mg/dL

Plus at least one of the two:

1. Tendon xanthomas in patient, or in first-¹⁾ or in second-degree²⁾ relative
2. DNA-based evidence of an *LDLR* mutation, familial defective apoB-100, or a PCSK9 mutation

Possible FH

Cholesterol criteria : < 16 years: total cholesterol > 260 mg/dL or LDL-C > 155 mg/dL
≥ 16 years: total cholesterol > 290 mg/dL or LDL-C > 190 mg/dL

Plus at least one of the two:

1. Family history of myocardial infarction : aged ≤ 60 years in first-degree¹⁾ relative or aged ≤ 50 years in second-degree²⁾ relative
2. Family history of raised total cholesterol :
 - > 290 mg/dL in adult first- or second-degree relative or
 - > 260 mg/dL in child, brother or sister aged < 16 years

1) First-degree relative: parents, siblings or children

2) Second-degree relative: grandparents, siblings of parents

FH, familial hypercholesterolemia ; LDL-C, low-density lipoprotein cholesterol ; LDL-R, low-density lipoprotein receptor ; apoB, apolipoprotein B.

Board of Directors

President	Myung-A Kim	Seoul National University
Vice-president	Jae Bum Kim	Seoul National University
Chairman	Donghoon Choi	Yonsei University
Secretary General	Chul Sik Kim	Yonsei University
Treasurer	Soon Jun Hong	Korea University
Director		
Planning Committee	Dae Jung Kim	Ajou University
Scientific Program Committee	Sang-Hak Lee	Yonsei University
Publication Committee	Jaetaek Kim	Chung-Ang University
Public Relations Committee	In-Kyung Jeong	Kyung Hee University
International Liaison Committee	Sung Hee Choi	Seoul National University
Insurance and Legislation Committee	Hyun Jae Kang	Seoul National University
Education Committee	Byung Jin Kim	Sungkyunkwan University
Clinical Practice Guideline Committee	Sang-Hyun Kim	Seoul National University
Clinic Research Committee	Sungha Park	Yonsei University
Basic Research Committee	Young Mi Park	Ewha Womans University
Food and Nutrition Committee	Min-Jeong Shin	Korea University
Without Portfolio	Ung Kim	Yeungnam University
	Kee Ho Song	Konkuk University
	Seonghoon Choi	Hallym University
Auditor	Young Joon Hong	Chonnam National University
	Goo Taeg Oh	Ewha Womans University
	Sung Rae Kim	The Catholic University of Korea

Committee of Clinical Practice Guideline

Director	Sang-Hyun Kim	Seoul National University
Secretary	Hack-Lyoung Kim	Seoul National University

Members	Byung Jin Kim	Sungkyunkwan University
	Eu Jeong Ku	Chungbuk National University
	Jae Hyeon Kim	Sungkyunkwan University
	Ji Hyun Kim	Dongguk University
	Hyeon Chang Kim	Yonsei University
	Jin Oh Na	Korea University
	Min Kyong Moon	Seoul National University
	Kwang-Yeol Park	Chung-Ang University
	Jae Hyoung Park	Korea University
	Jae Hyun Bae	Korea University
	Jang Won Son	The Catholic University of Korea
	Kee Ho Song	Konkuk University
	SuJin Song	Hannam University
	Aram Yang	Sungkyunkwan University
	Ye Seul Yang	The Catholic University of Korea
	Han Mo Yang	Seoul National University
	Mi Sun Oh	Hallym University
	Hoyoun Won	Chung-Ang University
	Tae-Hyun Yoo	Yonsei University
	Sang-Hak Lee	Yonsei University
	Eun-Jung Rhee	Sungkyunkwan University
	Chan Joo Lee	Yonsei University
	Jeong Hyun Lim	Seoul National University
	Suk Chon	Kyung Hee University
	Sae Young Jae	University of Seoul
	Sang-Ho Jo	Hallym University
	Iksung Cho	Yonsei University
	SeongHoon Choi	Hallym University
	Su-Yeon Choi	Seoul National University
	Keun-Sik Hong	Inje University
	Soon Jun Hong	Korea University
	Soon-Cheol Hong	Korea University



www.lipid.or.kr